Sponsored Content by EvotecReviewed by Ify IsiborAug 25 2026
High potency and increased specificity are just two of the properties that demonstrate the potential of peptide-based therapeutics as a drug class.
Image Credit: Shutterstock.com/YURIMA
Studies have shown that bioactive peptides can provide a wide variety of advantages, such as reducing blood pressure, exhibiting antimicrobial activity, lowering inflammation, and modulating immune function. In addition, peptide pharmaceuticals enable the targeting of biological pathways that were previously considered challenging to address, including protein–protein interactions.
As the number of peptide-based pharmaceutical candidates continues to increase, so too does the need for robust bioanalytical techniques. However, peptide pharmaceutical analysis poses distinct challenges, such as protein binding, non-specific binding, solubility problems, selectivity, and recovery.
Cyprotex recognizes that no single strategy is suitable for all peptides. The company's researchers design customized bioanalytical techniques tailored to individual peptide-based drugs, requiring only minimal compound information. These techniques have been successfully qualified and implemented to support non-GLP pharmacokinetic (PK) research.
Example one
Challenges of cyclic peptide analysis
Cyclic peptides pose substantial bioanalytical challenges owing to their intricate structures, elevated lipophilicity, extensive protein binding, and susceptibility to matrix influences.
These properties can cause low solubility, recovery, analyte adsorption, carryover, and problems achieving the selectivity and sensitivity necessary for dependable quantification in biological matrices, requiring highly sensitive LC-MS/MS techniques.
Effective bioanalysis of these molecules necessitates rigorous technique development, optimized sample preparation, thorough stability evaluation, and advanced mass spectrometry expertise to provide precise, repeatable pharmacokinetic and toxicokinetic data across preclinical and clinical studies.
Example two
Challenges of semaglutide bioanalysis
Semaglutide poses multiple bioanalytical challenges due to its peptide structure (4.1 kDa), extensive albumin binding, and tendency for non-specific adsorption. Achieving robust quantification requires precise optimization of sample preparation to maximize recovery while minimizing matrix impacts and analyte loss.
Additional challenges involve selecting appropriate precursor and product ions from several charge states, maintaining analyte stability during sample handling, and achieving the sensitivity needed to support pharmacokinetic research across a broad concentration range. This frequently requires a custom LC-MS/MS strategy tailored to the distinct physicochemical characteristics of the molecule.
View the case study
About Evotec
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure – faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us LinkedIn and X/Twitter @Evotec.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.